A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial ...
The efficacy and safety of donafenib combined with anti–PD-1 antibody plus transarterial chemoembolization (TACE) as first-line treatment for patients (pts) with hepatocellular carcinoma (HCC): A ...
Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with ...
Long-term efficacy and safety of disitamab vedotin monotherapy versus chemotherapy in bladder-preserving treatment of Chinese real-world patients with muscle-invasive urothelial cancer: A ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...
Systemic therapy de-escalation in early TNBC marks a shift in oncologic management, emphasizing the reduction of treatment intensity without compromising therapeutic efficacy. While the KEYNOTE-522 ...
Could endocrine therapy plus a CDK4/6 inhibitor offer a viable chemo-sparing option in hormone receptor (HR)-positive/HER2-positive breast cancer? In this eighth ...
Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...
Cancer has evolved to protect itself from our inherent immune responses, and some types of cancer cells have developed their own strategies to evade or withstand treatment. These pro-cancer shields ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results